Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris yesterday and set a price target of $41.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Maxwell Skor has given his Buy rating due to a combination of factors linked to Pharvaris’s deucrictibant franchise. He views the new analysis of immediate‑release and extended‑release deucrictibant, modeled across realistic dosing patterns, as demonstrating comfortable safety buffers that are grounded in both human pharmacokinetic simulations and nonclinical NOAEL data.
He also highlights supportive clinical evidence suggesting that using a bradykinin B2 receptor antagonist for prophylaxis alongside on‑demand treatment can be effective in managing breakthrough attacks. Together, these findings underpin the investment case for a dual IR+XR strategy that could broaden use, differentiate Pharvaris from single‑use competitors, and, in his view, justify an Overweight stance on PHVS shares.
In another report released on April 15, JonesTrading also reiterated a Buy rating on the stock with a $52.00 price target.